View all The Jacobus Report Blog Posts
Phil Jacobus has been involved in health care since 1977, when he visited China to sell equipment. He has done business in 35 countries and still travels extensively. Phil is active in charity, helps rural clinics and always tries to help DOTmed users when he can.
Phil is a member of AHRA, HFMA, AAMI and the Cryogenic Society of America. He has contributed to a number of magazines and journals and has addressed trade groups.
Phil's proudest achievement is that he has been happily married to his wife Barbara since 1989, who helped him found DOTmed in 1998.
You Must Be Logged In To Post A CommentRegistroRegistrarse es Gratis y Fácil. Disfruta de los beneficios del Mercado de Equipos Médicos Nuevos y Usados líder en el mundo. ¡Regístrate ahora! |
|
Don Bogutski
Phil: I too am encouraged by the FDA's approval of Amyvid
April 12, 2012 12:47
As is typical for newly approved drugs, the initial use for Amyvid is limited and diagnostic. However as an approved pharmaceutical, Amyvid will be available for physicians to prescribe for off label purposes. It seems likely that in the not too distant future Amyvid will find a variety of use as a prognostic tool in addition to it's diagnostic role. New drugs are emerging in rapid succession, spurred by the mining of data compiled from the genome mapping project as well as the evolving area of nano-pharmaceuticals. Someday soon, I predict that you will blog about Amyvid, or an analog drug, being paired with one of these new drugs to temporarily suspend the progress of Alzheimer's, or at least significantly slow it's progression to personality assassination and death.
to rate and post a comment